Skip to content
    Real-World Studies

    Most T-DXd discontinuations were due to progression in metastatic breast cancer cohort

    Licata et alCancers

    Clinical trial data have demonstrated that 30% to 60% of patients receiving trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) discontinue therapy in the absence of disease progression. To evaluate treatment persistence, cessation drivers, and post-progression pathways in clinical practice, a single-center retrospective observational study evaluated 93 consecutive patients with MBC who discontinued T-DXd between and . The cohort included 71.0% with HER2-positive, 26.9% with HER2-low, and 2.1% with HER2-zero disease.
    The primary reason for treatment discontinuation was disease progression (82.8%), reflecting a markedly lower rate of toxicity-related discontinuation than previously reported in pivotal trials. Discontinuations due to adverse events occurred in 14.0% of patients, while non-treatment-related factors and patient decision accounted for 2.2% and 1.1%, respectively. Interstitial lung disease (ILD) remained the predominant safety signal causing drug cessation, identified in 10.8% of the cohort.
    Overall median treatment duration reached 7.9 months, with longer exposure observed in HER2-positive cases compared to HER2-low and HER2-zero disease, as well as in patients who discontinued for reasons other than progression. Among evaluable patients, the overall response rate was 83.1% in HER2-positive tumors and 52.0% in HER2-low tumors. Following discontinuation, 80.6% of patients received subsequent systemic therapy. These findings highlight high treatment persistence and manageable toxicity profiles in real-world settings, while reinforcing the ongoing need for vigilant monitoring of interstitial lung disease.

    Key Takeaways

    • Disease progression was the primary driver of trastuzumab deruxtecan discontinuation in 82.8% of patients, with adverse event-related cessations occurring in only 14.0%.
    • Interstitial lung disease was the most frequent toxicity leading to treatment discontinuation, accounting for 10.8% of cases.
    • Evaluable patients achieved an overall response rate of 83.1% in HER2-positive tumors and 52.0% in HER2-low tumors, with 80.6% successfully transitioning to subsequent systemic therapy following discontinuation.